Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) Director Sells 4,500 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $6.98, for a total transaction of $31,410.00. Following the sale, the director now owns 74,438 shares in the company, valued at $519,577.24. This trade represents a 5.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Health Catalyst Stock Down 0.1 %

NASDAQ HCAT traded down $0.01 during trading on Friday, reaching $7.08. 560,524 shares of the company’s stock were exchanged, compared to its average volume of 562,055. The firm has a market capitalization of $430.80 million, a PE ratio of -5.24 and a beta of 1.31. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company’s fifty day simple moving average is $7.99 and its 200-day simple moving average is $7.46.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.22) EPS. Sell-side analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. raised its stake in shares of Health Catalyst by 5.8% in the 3rd quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock valued at $857,000 after acquiring an additional 5,687 shares in the last quarter. Geode Capital Management LLC increased its position in Health Catalyst by 4.9% during the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after acquiring an additional 66,896 shares during the period. Zacks Investment Management grew its position in Health Catalyst by 6.7% in the 3rd quarter. Zacks Investment Management now owns 296,121 shares of the company’s stock worth $2,410,000 after purchasing an additional 18,677 shares during the last quarter. State Street Corp increased its holdings in shares of Health Catalyst by 2.5% during the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after purchasing an additional 28,251 shares during the period. Finally, Quadrature Capital Ltd acquired a new position in shares of Health Catalyst during the third quarter valued at about $84,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Analyst Ratings Changes

HCAT has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Piper Sandler reiterated an “overweight” rating and issued a $12.00 target price (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Citigroup increased their target price on shares of Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Evercore ISI upped their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Finally, JPMorgan Chase & Co. lifted their target price on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Health Catalyst has a consensus rating of “Moderate Buy” and a consensus target price of $11.79.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.